Oncolytics' Cleverly Cut Subgroup Data Unlikely To Save Reolysin In NSCLC

August appears to be month of bad news for clinical developments in non-small cell lung cancer (NSCLC). Following Bristol-Myers Squibb Co.'s shocking Phase III failure for Opdivo (nivolumab) in first-line NSCLC, Oncolytics Biotech Inc. has also reported disappointing data for its lung cancer drug Reolysin.